Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Nov 10, 2021

Keywords

ClinConnect Summary

Interstitial lung disease (ILD) is a common pulmonary manifestation of idiopathic inflammatory myopathy (IIM), with an incidence ranging from 23.1 to 65%. The treatment of IIM patients with ILD is challenging, and the overall 5-year mortality is 50%. The disease process of ILD from stable or slow to rapid. Increased mortality and poor prognosis were observed, which needs active treatment. At present, according to the consensus of IIM-ILD experts, glucocorticoids as first-line treatment are often used in high doses, but have a variety of adverse reactions. Previous studies have shown that cy...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • meet the PM/DM diagnostic criteria according to Bohan-Peter
• • consistent with ILD diagnosis
• • predicted forced vital capacity (FVC) of at least 50%
• • patients who did not use immunosuppress agents (including but not limited to cyclophosphamide, cyclosporine, leflunomide, azathioprine, tacrolimus, etc.) at the time of screening, or who had stopped taking drugs for ≥3 months.
• Exclusion Criteria:
• • Anti MDA5 antibody positive DM and necrotizing myopathy
• • patients if they had other connective tissue diseases, an underlying cancer, a concomitant active infection.